1
|
Lee S, Shafer M, Reinke M, Uddin N, Sheng Q, Han M, Donovan D, O'Neill R. First demonstration of a fiber optic bolometer on a tokamak plasma (invited). Rev Sci Instrum 2022; 93:123515. [PMID: 36586957 DOI: 10.1063/5.0099546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 12/01/2022] [Indexed: 06/17/2023]
Abstract
A fiber optic bolometer (FOB) was demonstrated observing a fusion plasma for the first time at the DIII-D tokamak. A FOB uses a fiber optics-based interferometric technique that is designed to have a high sensitivity to temperature changes [75 mK/(W/m2) responsivity in high vacuum with 0.38 mK noise level] with a negligible susceptibility to electromagnetic interference (EMI) that can be problematic for resistive bolometers in a tokamak environment. A single-channel test apparatus was installed on DIII-D consisting of a measurement FOB and shielded reference FOB. The single-channel FOB showed a negligible increase in the noise level during typical plasma operations (0.39 mK) compared to the benchtop results (0.38 mK), confirming an insignificant EMI impact to the FOB. Comparisons to DIII-D resistive bolometers showed good agreement with the single-channel FOB, indicating that the FOB is comparable to a resistive bolometer when the impulse calibration is applied. The noise-equivalent power density of the calibrated FOB during a plasma operation was 0.55 W/m2 with an average sampling time of 20 ms. The major potential effect of ionizing radiation on the FOB would be the radiation-induced attenuation, which can be efficiently compensated for by adjusting the probing light power.
Collapse
Affiliation(s)
- S Lee
- Department of Nuclear Engineering, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - M Shafer
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - M Reinke
- Commonwealth Fusion Systems, Cambridge, Massachusetts 02139, USA
| | - N Uddin
- Department of Electrical and Computer Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - Q Sheng
- Department of Electrical and Computer Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Han
- Department of Electrical and Computer Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Donovan
- Department of Nuclear Engineering, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - R O'Neill
- General Atomics, San Diego, California 92121-1122, USA
| |
Collapse
|
2
|
Friedrich I, Donovan TJ, Paraforos A, Donovan D, Voss F. Minimally Invasive Surgical Ablation Combined with Postoperative Electrophysiological Evaluation and Intervention Is Highly Effective in the Treatment of Intermittent and Long-Standing Atrial Fibrillation. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
| | - T. J. Donovan
- Herz- und Thoraxchirurgie, Krankenhaus der Barmherzigen Brüder Trier, Trier, Deutschland
| | - A. Paraforos
- Herz- und Thoraxchirurgie, Krankenhaus der Barmherzigen Brüder Trier, Trier, Deutschland
| | - D. Donovan
- Herz- und Thoraxchirurgie, Krankenhaus der Barmherzigen Brüder Trier, Trier, Deutschland
| | - F. Voss
- Krankenhaus der Barmherzigen Brüder Trier, Trier, Deutschland
| |
Collapse
|
3
|
Looby T, Reinke M, Wingen A, Menard J, Gerhardt S, Gray T, Donovan D, Unterberg E, Klabacha J, Messineo M. A Software Package for Plasma-Facing Component Analysis and Design: The Heat Flux Engineering Analysis Toolkit (HEAT). Fusion Science and Technology 2022. [DOI: 10.1080/15361055.2021.1951532] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- T. Looby
- University of Tennessee–Knoxville, Nuclear Engineering Department, 1412 Circle Drive, Knoxville, Tennessee 37916
| | - M. Reinke
- Commonwealth Fusion Systems, 148 Sidney Street, Cambridge, Massachusetts 02139
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830
| | - A. Wingen
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830
| | - J. Menard
- Princeton Plasma Physics Laboratory, 100 Stellarator Road, Princeton, New Jersey 08540
| | - S. Gerhardt
- Princeton Plasma Physics Laboratory, 100 Stellarator Road, Princeton, New Jersey 08540
| | - T. Gray
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830
| | - D. Donovan
- University of Tennessee–Knoxville, Nuclear Engineering Department, 1412 Circle Drive, Knoxville, Tennessee 37916
| | - E. Unterberg
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830
| | - J. Klabacha
- Princeton Plasma Physics Laboratory, 100 Stellarator Road, Princeton, New Jersey 08540
| | - M. Messineo
- Princeton Plasma Physics Laboratory, 100 Stellarator Road, Princeton, New Jersey 08540
| |
Collapse
|
4
|
Paraforos A, Donovan J, Donovan D, Kraiker P, Friedrich I. External Stenting of Saphenous Vein Grafts in Coronary Artery Bypass Grafting: Two-Year Angiographic and Intravascular Ultrasound Follow-up from a Single-Center Randomized Cohort. Thorac Cardiovasc Surg 2020. [DOI: 10.1055/s-0040-1705401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
5
|
Benson C, Shea B, de Silva C, Donovan D, Holder P, Cooke S, Gallagher A. Physiological consequences of varying large shark exposure on striped bass (Morone saxatilis). CAN J ZOOL 2019. [DOI: 10.1139/cjz-2019-0173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Large marine predators often aggregate seasonally in discrete locations to take advantage of optimal foraging conditions, leading to spatial and temporal variation in their exposure on other species. However, our understanding of the impacts this exposure may have on the behavior and physiology of prey is poor, especially in marine systems. Here, we evaluated the non-consumptive effects of potential exposure to large sharks (white sharks, Carcharodon carcharias (Linnaeus, 1758)) on the stress physiology of an economically important teleost, the striped bass (Morone saxatilis (Walbaum, 1792)), off Cape Cod, Massachusetts, USA. We sampled fish in habitats that varied significantly in shark exposure across 5 months and over 2 years, evaluating blood physiology stress indicators (i.e., cortisol, glucose, and lactate concentrations) and reflex impairment. None of the blood parameters were influenced by shark exposure, although we did observe subtle temperature and seasonal effects. One of the three reflex tests (the vertical orientation test) was negatively affected by shark exposure, although the mechanistic basis for this finding is unclear. This work supports the notion that predictable sources of predation pressure tend not to manifest in stress-related costs in free-ranging prey, which has implications for shaping our understanding of how large sharks influence ecosystems through non-consumptive effects.
Collapse
Affiliation(s)
- C.W. Benson
- Beneath the Waves, P.O. Box 126, Herndon, VA 20172, USA
- Three Seas Program, Northeastern University, 430 Nahant Road, MA 01908, USA
| | - B.D. Shea
- Beneath the Waves, P.O. Box 126, Herndon, VA 20172, USA
- Three Seas Program, Northeastern University, 430 Nahant Road, MA 01908, USA
| | - C. de Silva
- Beneath the Waves, P.O. Box 126, Herndon, VA 20172, USA
| | - D. Donovan
- Thayer Academy, 745 Washington Street, Braintree, MA 02184, USA
| | - P.E. Holder
- Fish Ecology and Conservation Physiology Laboratory, Department of Biology and Institute of Environmental and Interdisciplinary Science, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada
| | - S.J. Cooke
- Fish Ecology and Conservation Physiology Laboratory, Department of Biology and Institute of Environmental and Interdisciplinary Science, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada
| | - A.J. Gallagher
- Beneath the Waves, P.O. Box 126, Herndon, VA 20172, USA
- Fish Ecology and Conservation Physiology Laboratory, Department of Biology and Institute of Environmental and Interdisciplinary Science, Carleton University, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada
| |
Collapse
|
6
|
Elder J, Stangeby P, Unterberg E, Abrams T, Boedo J, Donovan D, McLean A, Rudakov D, Wampler W, Watkins J. Evidence of near-SOL tungsten accumulation using a far-SOL collector probe array and OEDGE modelling in the DIII-D metal rings L-mode discharges. Nuclear Materials and Energy 2019. [DOI: 10.1016/j.nme.2019.03.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Ren J, Donovan D, Watkins J, Wang HQ, Rudakov D, Murphy C, McLean A, Lasnier C, Unterberg E, Thomas D, Boivin R. The surface eroding thermocouple for fast heat flux measurement in DIII-D. Rev Sci Instrum 2018; 89:10J122. [PMID: 30399945 DOI: 10.1063/1.5038677] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 06/15/2018] [Indexed: 06/08/2023]
Abstract
A novel type of surface eroding thermocouple (SETC) has been tested and demonstrated in the small angle slot (SAS) divertor of DIII-D for fast local heat flux measurements. The thermojunction of the SETC is formed between two thin (10 μm) ribbons, which are filed over to create microfiber junctions. These thermocouples are able to be exposed directly to the plasma at surface temperatures exceeding 2000 °C and are capable of sub-10 ms time resolution. Before installation in SAS, the SETCs were exposed in the lower DIII-D divertor during L-mode and H-mode discharges, from which results are presented. In preliminary tests, SETCs proved to be a qualified diagnostic to accurately measure both the intra-edge localized mode (ELM) and inter-ELM heat flux during H-mode shots with high frequency ELMs (hundreds of Hz) and to resolve heat flux profiles during strike point sweeps. The heat fluxes measured by using SETCs are consistent with the heat fluxes measured by using IR cameras and Langmuir probes. These new diagnostic capabilities will complement the existing IR camera measurements and will be of particularly significant value to measure surface heat flux in the SAS divertor or other regions where the IR camera lacks line of sight.
Collapse
Affiliation(s)
- J Ren
- University of Tennessee, Knoxville, Knoxville, Tennessee 37996-1410, USA
| | - D Donovan
- University of Tennessee, Knoxville, Knoxville, Tennessee 37996-1410, USA
| | - J Watkins
- Sandia National Laboratories, Livermore, California 94551, USA
| | - H Q Wang
- Oak Ridge Associated Universities, Oak Ridge, Tennessee 37830, USA
| | - D Rudakov
- University of California San Diego, San Diego, California 92093, USA
| | - C Murphy
- General Atomics, San Diego, California 92186-5608, USA
| | - A McLean
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Lasnier
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - E Unterberg
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - D Thomas
- General Atomics, San Diego, California 92186-5608, USA
| | - R Boivin
- General Atomics, San Diego, California 92186-5608, USA
| |
Collapse
|
8
|
Donovan D, Harrison L, McGinnis J, Ginsberg J, Crowther MA. Low-dose Oral Vitamin K Reliably Reverses Over-anticoagulation due to Warfarin. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615026] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryBackground: Patients receiving long-term warfarin frequently develop asymptomatic excessive prolongation of their international normalized ratio (INR) results. The most appropriate management strategy in these patients is unknown. This prospective cohort study was designed to address whether 1 mg of oral vitamin K effectively reduces the INR value of such patients. Methods: A prospective cohort study was performed in two tertiary care teaching hospitals, in which 62 patients receiving warfarin who had INR values between 4.5 and 10.0 received 1 mg of oral vitamin K. All patients had daily INR values and clinical assessments performed. Results: The mean INR value at presentation was 5.79 (95% confidence interval (CI) 5.48 to 6.09, range 4.5 to 9.5). Sixteen hours after receiving the 1 mg of oral vitamin K, the mean INR was 2.86 (95% CI 2.50 to 3.23). On the second and third days after vitamin K, the mean INR values were 2.20 (1.93 to 2.47) and 2.14 (1.85 to 2.44), respectively. No adverse events or bleeding complications were observed. In three patients (6%) the INR value rose between the time of vitamin K administration and the next INR determination; two patients received a further 2 mg dose of subcutaneous vitamin K. Conclusions: In patients receiving warfarin who have asymptomatic excessive prolongations in their INR results, 1 mg of oral vitamin K reliably reduces the INR to the therapeutic range within 24 h. This therapy is more convenient, less expensive, and might be safer than parenteral vitamin K. Thus, it should be considered in all non-bleeding patients receiving warfarin, who present with INR results of 4.5 to 9.5.Dr. Crowther is the recipient of a Medical Research Council of Canada Research Fellowship.Dr. Ginsberg is a Career Investigator of the Heart and Stroke Foundation of Ontario.
Collapse
|
9
|
Goulding RH, Caughman JBO, Rapp J, Biewer TM, Bigelow TS, Campbell IH, Caneses JF, Donovan D, Kafle N, Martin EH, Ray HB, Shaw GC, Showers MA. Progress in the Development of a High Power Helicon Plasma Source for the Materials Plasma Exposure Experiment. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1352429] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- R. H. Goulding
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | | | - J. Rapp
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - T. M. Biewer
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - T. S. Bigelow
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - I. H. Campbell
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - J. F. Caneses
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - D. Donovan
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - N. Kafle
- University of Tennessee, Bredesen Center, Knoxville, Tennessee 37996
| | - E. H. Martin
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - H. B. Ray
- University of Tennessee, Bredesen Center, Knoxville, Tennessee 37996
| | - G. C. Shaw
- University of Tennessee, Bredesen Center, Knoxville, Tennessee 37996
| | - M. A. Showers
- University of Tennessee, Bredesen Center, Knoxville, Tennessee 37996
| |
Collapse
|
10
|
Donovan D, Buchenauer D, Whaley J, Wright G, Parish C, Hu X. Characterization of He-induced Bubble Formation in Tungsten due to Exposure from an Electron Cyclotron Resonance Plasma Source. Fusion Science and Technology 2017. [DOI: 10.1080/15361055.2017.1333856] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- D. Donovan
- University of Tennessee-Knoxville, 1004 Estabrook Road, Knoxville, Tennessee 37996
| | - D. Buchenauer
- Sandia National Laboratory, 7011 East Avenue, Livermore, California 94550
| | - J. Whaley
- Sandia National Laboratory, 7011 East Avenue, Livermore, California 94550
| | - G. Wright
- Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139
| | - C.M. Parish
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831
| | - X. Hu
- Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831
| |
Collapse
|
11
|
van Zadelhoff GJ, Donovan D, Wandinger U, Daou D, Horn S, Hunerbein A, Fischer J, von Bismarck J, Filipitsch F, Docter N, Eisinger M, Lajas D, Wehr T. Overview of the Earthcare L2 Lidar Retrieval Chain. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611901003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Ward S, Bélanger M, Donovan D, Carrier N. Systematic review of the relationship between childcare educators' practices and preschoolers' physical activity and eating behaviours. Obes Rev 2015; 16:1055-70. [PMID: 26345462 DOI: 10.1111/obr.12315] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 07/31/2015] [Accepted: 07/31/2015] [Indexed: 12/01/2022]
Abstract
The role of childcare educators is important given that 81% of preschoolers living in developed countries receive childcare outside their home. Since children learn by observing and imitating others, childcare educators may play a role in promoting healthy eating behaviours and physical activity in young children. Six databases were searched for quantitative peer-reviewed, English or French primary studies reporting the correlates, predictors or effectiveness of childcare educators' practices on preschoolers' healthy eating and physical activity behaviours. Risk of bias was assessed using the Quality Assessment Tool for Quantitative Studies. Fifteen articles were included in this review: 10 measured physical activity levels and five assessed eating behaviours. The quality score was rated as low for eight of these articles, and as moderate for the remaining seven. Two of four cross-sectional studies reported a positive relationship between educators and children's behaviours. Eleven intervention studies reported significant favourable effects of interventions. Educators may play a positive role in promoting healthy behaviours in children, but this is mainly based on a small number of intervention type studies of low or moderate quality. The influence of specific components of educators' practices on children's healthy eating and physical activity behaviours remains inconclusive.
Collapse
Affiliation(s)
- S Ward
- Faculty of Medicine and Health Sciences, Université de Sherbrooke, Moncton, Canada
| | - M Bélanger
- Department of Family Medicine, Université de Sherbrooke, Moncton, Canada
| | - D Donovan
- Department of Community Health Sciences, Université de Sherbrooke, Moncton, Canada
| | - N Carrier
- École des sciences des aliments, de nutrition et d'études familiales, Université de Moncton, Moncton, Canada
| |
Collapse
|
13
|
Ward S, Bélanger M, Donovan D, Carrier N. Peer influence on healthy eating and physical activity of preschoolers: A systematic review. Eur J Public Health 2015. [DOI: 10.1093/eurpub/ckv171.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Brown L, Rosatte R, Fehlner-Gardiner C, Ellison J, Jackson F, Bachmann P, Taylor J, Franka R, Donovan D. Oral vaccination and protection of striped skunks (Mephitis mephitis) against rabies using ONRAB®. Vaccine 2014; 32:3675-9. [DOI: 10.1016/j.vaccine.2014.04.029] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Revised: 04/03/2014] [Accepted: 04/14/2014] [Indexed: 01/03/2023]
|
15
|
Mulrooney D, Nunnery S, Armstrong G, Ness K, Srivastava K, Donovan D, Metzger M, Krasin M, Joshi V, Durand JB, Robison L, Hudson M, Flamm S. Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography (CCTA) in Adult Survivors of Childhood Hodgkin Lymphoma. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Brown LJ, Rosatte RC, Fehlner-Gardiner C, Bachmann P, Ellison JA, Jackson FR, Taylor JS, Davies C, Donovan D. Oral vaccination and protection of red foxes (Vulpes vulpes) against rabies using ONRAB, an adenovirus-rabies recombinant vaccine. Vaccine 2013; 32:984-9. [PMID: 24374501 DOI: 10.1016/j.vaccine.2013.12.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 11/29/2013] [Accepted: 12/10/2013] [Indexed: 12/19/2022]
Abstract
Twenty-seven red foxes (Vulpes vulpes) were each offered a bait containing ONRAB, a recombinant oral rabies vaccine that uses a human adenovirus vector to express the immunogenic rabies virus glycoprotein; 10 controls received no vaccine baits. Serum samples collected from all foxes before treatment, and each week post-treatment for 16 weeks, were tested for the presence of rabies virus neutralizing antibody (RVNA). In the bait group, a fox was considered a responder to vaccination if serum samples from 3 or more consecutive weeks had RVNA ≥0.5 IU/ml. Using this criterion, 79% of adult foxes (11/14) and 46% of juveniles (6/13) responded to vaccination with ONRAB. Serum RVNA of adults first tested positive (≥0.5 IU/ml) between weeks 1 and 3, about 4 weeks earlier than in juveniles. Adults also responded with higher levels of RVNA and these levels were maintained longer. Serum samples from juveniles tested positive for 1-4 consecutive weeks; in adults the range was 2-15 weeks, with almost half of adults maintaining titres above 0.5 IU/ml for 9 or more consecutive weeks. Based on the kinetics of the antibody response to ONRAB, the best time to sample sera of wild adult foxes for evidence of vaccination is 7-11 weeks following bait distribution. Thirty-four foxes (25 ONRAB, 9 controls) were challenged with vulpine street virus 547 days post-vaccination. All controls developed rabies whereas eight of 13 adult vaccinates (62%) and four of 12 juvenile vaccinates (33%) survived. All foxes classed as non-responders to vaccination developed rabies. Of foxes considered responders to vaccination, 80% of adults (8/10) and 67% of juveniles (4/6) survived challenge. The duration of immunity conferred to foxes would appear adequate for bi-annual and annual bait distribution schedules as vaccinates were challenged 1.5 years post-vaccination.
Collapse
Affiliation(s)
- L J Brown
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada.
| | - R C Rosatte
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada
| | - C Fehlner-Gardiner
- Centre of Expertise for Rabies, Canadian Food Inspection Agency, 3851 Fallowfield Road, P.O. Box 11300, Station H, Ottawa, Ontario K2H 8P9, Canada
| | - P Bachmann
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada
| | - J A Ellison
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop G-33, Atlanta, GA 30329, USA
| | - F R Jackson
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop G-33, Atlanta, GA 30329, USA
| | - J S Taylor
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada
| | - C Davies
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada
| | - D Donovan
- Wildlife Research and Monitoring Section, Ontario Ministry of Natural Resources, Trent University, DNA Building, 2140 East Bank Drive, Peterborough, Ontario K9J 7B8, Canada
| |
Collapse
|
17
|
Chuang E, Stanton S, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff R, Cigler T, Moore A, Vahdat LT, Lane ME. Abstract P6-05-06: Association of HER2/neu single nucleotide polymorphism with trastuzumab-related cardiotoxicity. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment with trastuzumab prolongs overall survival when given to patients (pts) with Her2/neu+ breast cancer (BC). The primary toxicity of trastuzumab is cardiotoxicity and the incidence is estimated at 2-4% in the adjuvant setting. The mechanism for trastuzumab-induced cardiotoxicity is not known. Although Her2neu expression is usually not seen on cardiac myocytes, its expression has been shown to be upregulated after chemotherapy. Trastuzumab is a monoclonal antibody that binds to the extracellular domain of Her2/neu. We hypothesized that single nucleotide polymorphisms (SNPs) in the Her2/neu receptor may play a role in trastuzumab associated cardiotoxicity.
Methods: 140 pts with BC who were treated with chemotherapy and trastuzumab were enrolled into an IRB approved protocol at the Weill Cornell Medical College between July 2008 and March 2013. Cardiotoxicity was defined as either symptomatic CHF, or a decline in LVEF of 15% (or if LVEF <55% a decline in LVEF of 10%) that required management with medications and led to temporary or permanent discontinuation of trastuzumab. 11 nonsynonomous human ErbB2 SNPs were identified in the National Center for Biotechnology Information SNP database (rs1136201, rs2172826, rs28933368, rs28933369, rs28933370, rs34602395, rs36085723, rs4252633, rs55943169, rs56366519, rs61552325). Genotyping of SNPs was performed on DNA prepared from blood or buccal washes. The relationship between SNP characteristics and cardiotoxicity status was assessed by the chi-square test and multivariable logistic regression analysis.
Results: 140 subjects (29 with cardiotoxicity and 111 without) had 11 SNPs sequenced. Median age of subjects was 56 years (range: 32-85), mean baseline LVEF was 65% (±6%). 16.4% of subjects had hypertension (HTN). 80% of patients were Caucasian, 10% East Asian, 7.1% African American, 2.9% South Asian. There were two SNPs for which there was variation seen among subjects: rs 1136201 (corresponding to codon 655) and rs61552325 (codon 1170). The frequencies of the codon 655 polymorphisms were: AA (Ile/Ile) 67.9%, AG (Ile/Val) 29.3%, and GG (Val/Val) 2.9%. The frequencies of the codon 1170 polymorphisms were: CC (Pro/Pro) 20.7%, GC (Ala/Pro) 45.7%, and GG (Ala/Ala) 33.6%. There was no association observed between the codon 655 polymorphism and cardiotoxicity (p = 0.96). A significant association between cardiotoxicity and the codon 1170 polymorphism was observed, with subjects having cardiotoxicity being more likely to carry the CC allele compared with subjects without cardiotoxicity (34.5% vs 17.1%, p = 0.04). This association persisted after multivariable adjustment for age, race, and HTN status (adjusted OR = 2.60, 95% CI = 1.02-6.62, p = 0.046).
Conclusion: In this study, the Her2/neu 1170 Pro/Pro polymorphism was associated with trastuzumab cardiotoxicity. If confirmed in a larger series, this polymorphism could be used to identify pts who may be at increased risk for cardiotoxicity and who may benefit from treatments associated with less cardiotoxicity. Furthermore, the Her2/neu 1170 SNP has previously been implicated as a minor histocompatibility antigen, and our findings raise the possibility that immune mediated mechanisms may play a role in trastuzumab related cardiotoxicity.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-06.
Collapse
Affiliation(s)
- E Chuang
- Weill Cornell Medical College, New York, NY
| | - S Stanton
- Weill Cornell Medical College, New York, NY
| | - MM Ward
- Weill Cornell Medical College, New York, NY
| | - P Christos
- Weill Cornell Medical College, New York, NY
| | - R Sanford
- Weill Cornell Medical College, New York, NY
| | - C Lam
- Weill Cornell Medical College, New York, NY
| | - MV Cobham
- Weill Cornell Medical College, New York, NY
| | - D Donovan
- Weill Cornell Medical College, New York, NY
| | - R Scheff
- Weill Cornell Medical College, New York, NY
| | - T Cigler
- Weill Cornell Medical College, New York, NY
| | - A Moore
- Weill Cornell Medical College, New York, NY
| | - LT Vahdat
- Weill Cornell Medical College, New York, NY
| | - ME Lane
- Weill Cornell Medical College, New York, NY
| |
Collapse
|
18
|
Sobey K, Walpole A, Rosatte R, Fehlner-Gardiner C, Donovan D, Bachmann P, Coulson S, Beresford A, Bruce L, Kyle C. An assessment of ONRAB® oral rabies vaccine persistence in free-ranging mammal populations in Ontario, Canada. Vaccine 2013; 31:2207-13. [DOI: 10.1016/j.vaccine.2013.02.057] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Revised: 02/07/2013] [Accepted: 02/27/2013] [Indexed: 11/29/2022]
|
19
|
Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Hurtado Rúa SM, Benkert S, Mathijsen Greenwood C, Zelkowitz R, Warren JD, Lane ME, Mittal V, Rafii S, Vahdat LT. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol 2013; 24:1491-8. [PMID: 23406736 DOI: 10.1093/annonc/mds654] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence. PATIENTS AND METHODS This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs. RESULTS Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depleted compared with 41% luminal subtypes. In copper-depleted patients only, there was a significant reduction in EPCs/ml by 27 (P = 0.04). Six patients relapsed while on study, of which only one patient had EPCs maintained below baseline. The 10-month relapse-free survival was 85.0% (95% CI 74.6%-96.8%). Only grade 3/4 toxicity was hematologic: neutropenia (3.1% of cycles), febrile neutropenia (0.2%), and anemia (0.2%). CONCLUSIONS TM is safe and appears to maintain EPCs below baseline in copper-depleted patients. TM may promote tumor dormancy and ultimately prevent relapse.
Collapse
Affiliation(s)
- S Jain
- Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Jain S, Carlson K, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Ramnarain A, Carey B, Ward M, Lane M, Strickland S, Vahdat L. Abstract P1-15-07: Ixabepilone-associated peripheral neuropathy in metastatic breast cancer patients and its effects on the ultrastructure of neurons. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-15-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Peripheral neuropathy is a dose-limiting toxicity of most microtubule-stabilizing chemotherapeutic agents. Ixabepilone, a semisynthetic analog of the natural epothilone B, has activity in a wide range of tumors including taxane-resistant disease. In this study, we sought to understand the effect of ixabepilone on the development of peripheral neuropathy both clinically and its effect at the ultrastructural level of the peripheral nerves and circulating factors over time. Parallel studies in animal models of neuropathy were performed at the same time (Proc AACR 2010 Abstract 4184).
Methods: This open-label, non-randomized phase II study enrolled 14 patients with metastatic breast cancer. Ixabepilone was administered by 2 schedules: the FDA approved dose of 40 mg/m2 every 3 weeks (q3w) and 16 mg/m2 on day 1, 8, and 15 of a 28-day cycle (weekly). Five controls, 2 with residual taxane-associated peripheral neuropathy and 3 with no prior chemotherapy or peripheral neuropathy, were also accrued. The primary objectives were to characterize the natural history of ixabepilone-associated peripheral neuropathy using the Total Neuropathy Score Clinical (TNSc) assessment tool prior to each cycle and to correlate changes in the ultrastructure of dermal myelinated nerve fibers via a 3 mm punch biopsy of an area 10 cm above the lateral malleolus every 2 cycles with electron microscopy (EM), as well as circulating factors (both inflammatory and neurotrophic) considered to be important in the pathogenesis of chemotherapy-induced peripheral neuropathy. Secondary objectives included progression-free survival (PFS) and non-neurologic toxicity.
Results: 14 patients were enrolled and were equally divided between the 2 schedules of ixabepilone chemotherapy. There were no differences in baseline characteristics between the two groups. Mean age was 54 years (range 32–71). Mean number of previous chemotherapy regimens was 3.5 (range 0–8). 57% of patients had received a taxane in the adjuvant setting and 64% in the metastatic setting. The mean neuropathy score (TNSc) at baseline was 4.6 (range 1–11). At a mean cumulative dose of 185 mg/m2, the TNSc with ixabepilone q3w schedule was 3.7 points higher/worse (95% CI: 2.2–5.3, p = 0.03) than the mean score observed in patients on the weekly schedule. The sensory component was most significantly affected, predominantly numbness. In 3 patients, the chemotherapy schedule was changed from every 3 weeks to weekly due to > grade 2 toxicity at a mean cumulative dose of 107 mg/m2, and TNSc decreased/improved by 2.7 points. PFS in patients on q3w ixabepilone was 133 days (range 28–280) and in patients on weekly ixabepilone was 179 days (range 66–336), nonsignificant. Evaluation of EM and circulating factors is ongoing.
Conclusions: Weekly ixabepilone appears to have a more favorable neurotoxicity profile compared to the standard q3w schedule. Integration of the EM data and the circulating factor data are underway and will be presented. Ixabepilone-associated peripheral neuropathy may improve in patients switched to weekly ixabepilone without compromising efficacy.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-15-07.
Collapse
Affiliation(s)
- S Jain
- Weill Cornell Medical College; Rockefeller University
| | - K Carlson
- Weill Cornell Medical College; Rockefeller University
| | - E Chuang
- Weill Cornell Medical College; Rockefeller University
| | - T Cigler
- Weill Cornell Medical College; Rockefeller University
| | - A Moore
- Weill Cornell Medical College; Rockefeller University
| | - D Donovan
- Weill Cornell Medical College; Rockefeller University
| | - C Lam
- Weill Cornell Medical College; Rockefeller University
| | - MV Cobham
- Weill Cornell Medical College; Rockefeller University
| | - S Schneider
- Weill Cornell Medical College; Rockefeller University
| | - A Ramnarain
- Weill Cornell Medical College; Rockefeller University
| | - B Carey
- Weill Cornell Medical College; Rockefeller University
| | - M Ward
- Weill Cornell Medical College; Rockefeller University
| | - M Lane
- Weill Cornell Medical College; Rockefeller University
| | - S Strickland
- Weill Cornell Medical College; Rockefeller University
| | - L Vahdat
- Weill Cornell Medical College; Rockefeller University
| |
Collapse
|
21
|
Jain S, Kornhauser N, Lam C, Ward MM, Chuang E, Cigler T, Moore A, Donovan D, Cobham MV, Schneider S, Hurtado RSM, Lane ME, Mittal V, Vahdat LT. Abstract P6-11-04: Targeting the tumor microenvironment: tetrathiomolybdate decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-11-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bone marrow-derived endothelial progenitor cells (EPCs) constitute an important part of the tumor microenvironment and are critical for metastatic progression in preclinical models and breast cancer patients (Jain et al, Breast Cancer Res Treat, 2012). Tetrathiomolybdate (TM), a copper-depleting compound inhibits angiogenesis, tumor growth, and metastasis. This study explores the effect of TM on EPCs in patients at high risk for breast cancer recurrence.
Methods: This phase II study enrolled stage 3, 4 without evidence of disease (NED), and any node-positive triple negative breast cancer patient. Only concomitant hormone therapy was allowed. Patients received induction TM 180 mg daily at baseline followed by an equal or lower daily dose (median 100 mg, range 0–140) to maintain ceruloplasmin (Cp) level < 17 mg/dl (target for copper depletion). We monitored EPCs (CD45dim/CD133+/VEGFR2+), Cp, CEA, and CA15-3 at baseline and monthly. Wilcoxon signed-rank was used to compare Cp and EPC levels between baseline and subsequent time points. All p-values were two-sided with statistical significance evaluated at the 0.05 alpha level.
Results: 50 patients (33 adjuvant, 17 Stage 4 NED, and 22 triple negative) were enrolled. In the first 40 patients enrolled who had received at least 24 months of TM, EPC and Cp data were available for analysis. Of these 40 patients, 1 patient did not take TM due to patient preference, and 736 cycles of TM (average 18.9 per patient) were administered. Median age was 50 years (range 29–66). Median number of tumor size and positive lymph nodes among adjuvant patients were 3.5 cm (range 1.2–7) and 9 (range 0–42), respectively. Of the patients receiving hormone therapy, 11 patients were on tamoxifen and 16 patients were on an aromatase inhibitor. Median baseline Cp level was 30 mg/dL (range 20–47). 71% patients adequately copper depleted at month 1 to a mean Cp of 14.8 mg/dL. A larger proportion of triple negative patients copper depleted (82%) compared to hormone receptor positive subtypes (47%) and HER2/neu positive subtypes (67%). Median EPCs/ml decreased from baseline to last dose by 16 in patients that achieved the copper depletion target, p = 0.014. Conversely, in patients that did not copper deplete, median EPCs/ml increased by 136, p = 0.005. Of the 50 patients on study, 7 patients relapsed in which a significant increase in EPCs preceded an objective clinical relapse and a tumor marker rise by a median of 1 month. Only grade 3/4 toxicity was hematologic, occurred in 49 cycles (6.7%), and resolved in 5–13 days with TM held and resumed at a lower dose.
Conclusions: TM is a well-tolerated oral copper chelator that may contribute to maintaining EPCs below baseline in copper-depleted patients. Molecular subtype may impact on the ability to copper deplete. EPCs may have potential as a surrogate marker for early relapse and as a therapeutic target for interrupting the metastatic progression.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-11-04.
Collapse
Affiliation(s)
- S Jain
- Weill Cornell Medical College
| | | | - C Lam
- Weill Cornell Medical College
| | - MM Ward
- Weill Cornell Medical College
| | | | | | - A Moore
- Weill Cornell Medical College
| | | | | | | | | | - ME Lane
- Weill Cornell Medical College
| | | | | |
Collapse
|
22
|
Jain S, Cohen JA, Ward MM, O'Loughlin J, Boeck M, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham ME, Schneider SE, Christos PJ, Lane ME, Baergen R, Mittal V, Rafii S, Vahdat LT. The effect of tetrathiomolybdate on endothelial progenitor cells in patients at high risk for breast cancer recurrence. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Jain S, Ward MM, O'Laughlin J, Chuang E, Cigler T, Moore A, Donovan D, Schneider S, Cobham M, Wiener N, Lam C, Christos PJ, Lane ME, Rafii S, Vahdat LT. Abstract P2-16-14: The Effect of Tetrathiomolybdate (TM) on Circulating Endothelial Progenitor Cells in Women at Moderate to High Risk of BC Recurrence. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-16-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bone marrow (BM) derived endothelial progenitor cells (EPCs) are critical to tumor angiogenesis, are increased in BC patients (pts) and are probably an early marker for paclitaxel response. Copper is required for angiogenesis, and pre-clinical data suggest that TM, a copperdepleting compound, inhibits angiogenesis and maintains tumor dormancy through unknown mechanisms. We sought to measure the effect of TM on BM derived EPCs in pts at high risk of BC recurrence and to evaluate the effect of copper depletion on their absolute number. Methods: This analysis is part of an ongoing phase II study of TM in BC pts at high risk of recurrence defined as any node positive triple negative (TN) BC, Stage III or IV with no evidence of disease (NED). All therapy other than hormonal was completed at least 6 weeks prior to study. Treatment: TM 180 mg daily to achieve a target ceruloplasmin (Cp) level of 5-15 mg/dL (copper depletion), and then 100 mg daily. We monitored levels of EPCs (CD45dim, CD133+, VEGFR2+), CEA, CA15-3, and Cp at baseline and monthly. Imaging studies are done every 6 months (mos). Initial study duration is 24 mos. Extension study for an additional 24 mos in selected pts. Results: 40 pts are enrolled and 566 cycles of TM have been administered. Adjuvant: 28 pts, Stage 4 NED: 12 pts, Triple negative: 11 pts (4 stage 4 NED, 7 Adjuvant). Median age is 51 yrs (range: 29-64). Median number of positive lymph nodes among Stage 2/3 pts is 7 (4-42). Median baseline Cp level is 29 mg/dL (21-47). Among 36 pts who have reached target Cp, the median time to target is 4 wks (2-20 wks). Four pts discontinued treatment before reaching target. The median baseline EPCs is 0.01 cells/ml (0.0-0.286), and the majority of pts’ EPCs were maintained below baseline when Cp levels remained below target (i.e. copper depleted). Toxicity: Grade 3/4 neutropenia occurred in 15 cycles (2.6%) with 1 pt with febrile neutropenia. One cycle was complicated by Grade 3 anemia. All resolved 5-13 days later with TM held and resumed at a lower dose. No other grade 3/4 toxicity was observed. Six pts were diagnosed with recurrent breast cancer at 1, 2, 2, 9, 10 and 10 mos. An EPC rise preceded an abnormal marker or overt relapse by 3-5 months in 4 of 6 pts (2 pts too early to tell). Conclusions: TM is well tolerated in breast cancer patients. TM might contribute to maintaining EPCs below baseline in pts who are copper depleted. We postulate that the increased EPCs noted in 4 pts with recurrent disease 2-4 months prior to overt relapse could represent the turning on of an angiogenic switch, resulting in an outpouring of BM derived EPCs to the new site of metastasis. Other studies geared toward understanding the mechanism for metastases are underway. The trial continues to accrue.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-16-14.
Collapse
Affiliation(s)
- S Jain
- Weill Cornell Medical College, New York, NY
| | - MM Ward
- Weill Cornell Medical College, New York, NY
| | | | - E Chuang
- Weill Cornell Medical College, New York, NY
| | - T Cigler
- Weill Cornell Medical College, New York, NY
| | - A Moore
- Weill Cornell Medical College, New York, NY
| | - D Donovan
- Weill Cornell Medical College, New York, NY
| | | | - M Cobham
- Weill Cornell Medical College, New York, NY
| | - N Wiener
- Weill Cornell Medical College, New York, NY
| | - C Lam
- Weill Cornell Medical College, New York, NY
| | | | - ME Lane
- Weill Cornell Medical College, New York, NY
| | - S Rafii
- Weill Cornell Medical College, New York, NY
| | - LT. Vahdat
- Weill Cornell Medical College, New York, NY
| |
Collapse
|
24
|
Chuang E, Wiener N, Christos P, Kessler R, Cobham M, Donovan D, Goldberg GL, Caputo T, Doyle A, Vahdat L, Sparano JA. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol 2010; 21:2075-2080. [PMID: 20357034 DOI: 10.1093/annonc/mdq080] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. METHODS Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. RESULTS Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m(2) on days 1, 8, and 15 plus PLD 30 mg/m(2) given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. CONCLUSION Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.
Collapse
Affiliation(s)
| | | | - P Christos
- Division of Biostatistics and Epidemiology, Department of Public Health, Weill Cornell Medical College, New York, NY
| | | | | | | | - G L Goldberg
- Department of Obstetrics and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - T Caputo
- Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY
| | - A Doyle
- Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD
| | | | - J A Sparano
- Department of Medicine and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
25
|
Wiggins MC, Woolums AR, Hurley DJ, Sanchez S, Ensley DT, Donovan D. The effect of various Mycoplasma bovis isolates on bovine leukocyte responses. Comp Immunol Microbiol Infect Dis 2010; 34:49-54. [PMID: 20189247 DOI: 10.1016/j.cimid.2010.02.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/2010] [Indexed: 11/16/2022]
Abstract
Mycoplasma bovis (M. bovis) contributes to a number of clinical syndromes in cattle; in particular, chronic pneumonia that is poorly responsive to therapy has been increasingly recognized as an important cause of morbidity, mortality, and financial loss. M. bovis impairs host immune function, but little is known about whether field isolates vary significantly in their effect on immune function. This research tested the hypothesis that different field isolates vary in their ability to suppress cellular metabolism and cellular production of radical oxygen species (ROS) by bovine leukocytes. Total blood leukocytes from 6 cattle were exposed to six field isolates, two diagnostic lab isolates, and two high passage laboratory isolates of M. bovis, and ROS production was measured by oxidation of dihydrorhodamine 123 (DHR-123). Cellular metabolism was measured by reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Significant differences in the response to some field isolates were identified. Three field isolates and both diagnostic lab isolates significantly decreased ROS production by leukocytes from multiple cattle, while the high pass laboratory isolates did not. In contrast, MTT reduction was not significantly impaired by any of the M. bovis strains tested. M. bovis impairs ROS production by bovine leukocytes; the magnitude of the effect appears to be isolate-dependent, and is not related to a general impairment of cellular metabolism. Chronic M. bovis infection in some cattle may be related to impaired ability of leukocytes to produce ROS when exposed to M. bovis.
Collapse
Affiliation(s)
- M C Wiggins
- Dept. of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, 30602, United States
| | | | | | | | | | | |
Collapse
|
26
|
Vahdat L, Ward M, Chuang E, Cigler T, Moore A, Donovan D, Cobham M, Schpero J, Wiener N, Blinder V, Christos P, Rafii S, Lane M. A Phase II Trial Tetrathiomolybdate (TM), a Copper Depleting Compound, and Its Effect on Circulating Endothelial Progenitor Cells (EPCs) in Patients with Breast Cancer (BC) at High Risk of Recurrence. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: EPCs are critical to tumor angiogenesis, are increased in BC patients (pts) and are probably an early marker for paclitaxel response. Copper is required for angiogenesis, and pre-clinical data suggest that TM, a copper-depleting compound, inhibits angiogenesis and maintains tumor dormancy. We sought to measure the effect of TM on circulating endothelial progenitor cells (EPCs) in pts at high risk of BC recurrence and to evaluate the effect of copper depletion on EPCs. Methods: This analysis is part of an ongoing phase II study of TM in BC pts at high risk of recurrence defined as any node positive triple negative (TN) BC, Stage III or IV with no evidence of disease (NED). All therapy other than hormonal was completed at least 6 weeks prior to study. Treatment: TM 180 mg daily to achieve a target ceruloplasmin (Cp) level of 5-15 mg/dL (copper depletion), and then 100 mg daily. We monitored levels of EPCs (CD45dim, CD133+, VEGFR2+), CEA, CA15-3, and Cp at baseline and monthly. Imaging studies are done every 6 months (mos). Results: 28 pts are enrolled and 304 cycles of TM have been administered. Adjuvant: 20 pts, Stage 4 NED: 8 pts, Triple negative: 8 pts (5 stage IV NED, 3 Adjuvant) The median age is 51 years (range: 29-64), median number of positive lymph nodes among Stage III patients is 7 (4-42). The median baseline Cp level was 28 mg/dL (21-43). Among 21 patients who have reached target Cp, the median time to target is 6 weeks (2-16 weeks). Two pts discontinued treatment before reaching target. The median baseline EPCs is 17.38 cells/ml (0.0-286.1) Although there was a trend toward increased EPCs at month 1, this was not statistically significant (p=0.8964) and the majority of pts EPCs were maintained below baseline over time when Cp levels were below target (ie. copper depleted). Toxicity: Grade 3/4 neutropenia occurred in 3 patients (0.02%) with 1 pt with febrile neutropenia. All resolved 5-13 days later with TM held and resumed at a lower dose in 2 patients. No other grade 3/4 toxicity was observed. Three patients were diagnosed with recurrent breast cancer at 1, 9 and 10 mos. An EPC rise preceded an abnormal marker or overt relapse by 3-5 months in 2 of 3 pts. Conclusions: TM is well tolerated in breast cancer patients. TM might contribute to maintaining EPCs below baseline in pts who are copper depleted. We postulate that the increased EPCs noted in both patients with recurrent disease 2-4 months prior to overt relapse could represent the turning on of an angiogenic switch, resulting in an outpouring of CEPCs to the new site of metastasis. Other studies geared toward understanding the mechanism for metastases are underway. The trial continues to accrue.Supported by the Susan B Komen for the Cure, NY Community Trust, Breast Cancer Alliance of Greenwich and the Madeline and Stephen Anbinder Foundation.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6090.
Collapse
Affiliation(s)
| | - M. Ward
- 1Weill Cornell Medical College, NY,
| | | | | | - A. Moore
- 1Weill Cornell Medical College, NY,
| | | | | | | | | | | | | | - S. Rafii
- 3Weill Cornell Medical College, NY,
| | - M. Lane
- 1Weill Cornell Medical College, NY,
| |
Collapse
|
27
|
Blinder VS, Lane ME, Ward MM, Chuang E, Cigler T, Moore AL, Scheff RJ, Cobham ME, Donovan D, Rice D, Christos PJ, Vahdat LT. The effect of tetrathiomolybdate on circulating endothelial progenitor cells in patients with breast cancer at high risk of recurrence. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1036
Background: Endothelial progenitor cells are critical to tumor angiogenesis and are increased in breast cancer patients. Copper is required for angiogenesis, and pre-clinical data suggest that tetrathiomolybdate (TM), a copper-depleting compound, inhibits angiogenesis and maintains tumor dormancy. We sought to measure circulating endothelial progenitor cells (CEPCs) in patients at high risk of breast cancer recurrence and to evaluate the effect of copper depletion on CEPCs.
 Methods: This analysis is part of an ongoing phase II study of TM in breast cancer patients at high risk of recurrence defined as Stage III or IV with no evidence of disease. All therapy other than hormonal was completed at least 6 weeks prior to study. Treatment: TM 180 mg daily to achieve a target ceruloplasmin (Cp) level of 5-15 mg/dL (copper depletion), and then 100 mg daily. We monitored levels of CEPCs (CD45dim, CD133+, VEGFR2+), CEA, CA15-3, and Cp at baseline and monthly. CEPCs were also measured in 6 healthy controls.
 Results: To date we have enrolled 16 patients with a median age of 51 years (range: 29-64). 14 had a history of Stage III disease, while 2 were considered to be Stage IV with no evidence of disease. The median number of positive lymph nodes among Stage III patients was 7 (1-42), with 2 patients having received neoadjuvant therapy. The median baseline Cp level was 28 mg/dL (21-41). Among 12 patients who have reached target Cp, the median time to target was 1 month (1-3 months). The median follow-up of the 4 patients who have not yet achieved target is 2.5 months. 1 of these discontinued treatment before reaching target. The median baseline CEPCs was lower in patients than healthy controls: 0.022 cells/μL (0.000-0.286) vs. 0.123 cells/μL (0.058-0.418); p=0.03. There was no statistically significant change in CEPCs from baseline over time.
 One patient was diagnosed with recurrent breast cancer at month 10. A rise in her CEPCs preceded a rise in a CEA and overt relapse by 1 and 5 months, respectively.
 Toxicity: Grade 3/4 neutropenia occurred in 3 patients. TM was held, and this resolved 5-13 days later, after which TM was resumed. No other grade 3/4 toxicity was observed. One patient discontinued TM due to diarrhea attributed to the lactose used in the compounding of TM.
 Conclusions: TM is well tolerated in breast cancer patients. We postulate that the increased CEPCs noted in one patient at month 4, 6 months prior to overt relapse, could represent the “turning on” of an angiogenic switch, resulting in an outpouring of CEPCs to the new site of metastasis. The trial is ongoing, and with additional follow-up other trends might emerge.
 Supported by Komen for the Cure Foundation, Anbinder Foundation, NY Community Trust and Breast Cancer Alliance of Greenwich.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1036.
Collapse
Affiliation(s)
- VS Blinder
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - ME Lane
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - MM Ward
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - E Chuang
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - T Cigler
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - AL Moore
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - RJ Scheff
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - ME Cobham
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - D Donovan
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - D Rice
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| | - PJ Christos
- 2 Department of Public Health, Weill Medical College of Cornell University, New York, NY
| | - LT Vahdat
- 1 Department of Medicine, New York Presbyterian Hospital–Weill Cornell Medical College, New York, NY
| |
Collapse
|
28
|
Slate D, Rupprecht CE, Donovan D, Badcock J, Messier A, Chipman R, Mendoza M, Nelson K. Attaining raccoon rabies management goals: history and challenges. Dev Biol (Basel) 2008; 131:439-447. [PMID: 18634506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Prior to 1977, raccoon (Procyon lotor) rabies was confined to the southeastern US. Translocations led to emergence of this rabies variant in the mid-Atlantic states, followed by spread northerly to northeast Ohio and Ontario, Quebec, and New Brunswick, Canada. Raccoon rabies is currently contiguous from southwest Alabama to southeastern Canada. Since 1998, state, federal, county and municipal as well as Canadian and Mexican experts have collaborated on goals and strategies to prevent raccoon rabies spread in North America. Coordinated programmes have been established from Maine to Alabama. Successes have been realized through strategies that rely heavily on oral vaccination. International coordination targeting raccoon rabies continues in eastern Canada, where contingency actions have led to elimination or near elimination in Ontario and New Brunswick. However, increasingly, focus in the US has been directed toward contingency actions to "hold-the-line" where raccoon rabies threatens to spread to new areas, rather than on raccoon rabies elimination. We report on the challenges of achieving enhanced rabies surveillance, containment of raccoon rabies, and local elimination of raccoon rabies, as well as the need for international coordination in meeting these challenges.
Collapse
Affiliation(s)
- D Slate
- United States Department of Agriculture, Animal and Plant Heath Inspection Service, Wildlife Services, Concord, NH 03301, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Vahdat LT, Cohen DJ, Zipin D, Lo KS, Donovan D, Savage D, Tiersten A, Nichols G, Troxel A, Hesdorffer CS. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-γ after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant 2007; 40:267-72. [PMID: 17563739 DOI: 10.1038/sj.bmt.1705692] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
High-risk primary breast cancer patients treated with high-dose chemotherapy (HDC) and stem cell support (SCS) have shown prolonged disease-free survival (DFS) in many studies; however, only one trial has demonstrated an overall survival benefit (OS). We hypothesize that the period following myeloablative therapy is ideal for immunologic manipulation and studied the effects of two different methods of immunotherapy following HDC with SCS aimed at the window of immune reconstitution. Seventy-two women with high-risk stage II or III breast cancer were randomized following HDC to receive either interleukin 2 (IL-2) at 1 million units/m(2) SQ daily for 28 days or combined cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m(2) SQ every 2 days from day +7 to +28. At a median follow-up of 67 months, no significant difference was observed in DFS or OS between the two treatment groups. The IL-2 arm had a 59% DFS (95% CI (0.45, 0.78)) and a 72% OS (95% CI (0.58, 0.88)) at 5 years. The CsA/INF-gamma arm had a similar outcome with a 55% DFS (95% CI (0.40, 0.76)) and a 78% OS (95% CI (0.65, 0.94)) at 5 years. Treatment was well tolerated, without increased toxicity.
Collapse
Affiliation(s)
- L T Vahdat
- Weill Medical College of Cornell University, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Rosatte RC, Power MJ, Donovan D, Davies JC, Allan M, Bachmann P, Stevenson B, Wandeler A, Muldoon F. Elimination of arctic variant rabies in red foxes, metropolitan Toronto. Emerg Infect Dis 2007; 13:25-7. [PMID: 17370512 PMCID: PMC2725809 DOI: 10.3201/eid1301.060622] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
To control the arctic variant of rabies virus in red foxes, 332,257 bait doses containing live, attenuated Evelyn-Rokitnicki-Abelseth rabies vaccine were distributed in greater metropolitan Toronto during 1989–1999. Human and pet contact with bait was minimal, and no adverse reactions to the vaccine were noted. Significantly fewer rabid foxes were found during the 17 years after fox baiting (5 cases during 1990–2006) than in the 17 years before (96 cases during 1973–1989). The last report of a rabid fox in metropolitan Toronto was in 1996 (reporting period through September 2006), which confirms that distributing oral rabies vaccine bait is a feasible tactic for the control of rabies in foxes in urban environments.
Collapse
Affiliation(s)
- R C Rosatte
- Ontario Ministry of Natural Resources, Trent University, Peterborough, Ontario, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Naik R, Jin D, Chuang E, Gold E, Tousimis E, Christos P, De Dalmas T, Donovan D, Rafii S, Vahdat L. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
616 Background: Tumor growth and metastasis is dependent on neo-angiogenesis. Both pre-existing and circulating vascular cells have been shown to contribute to the assembly of tumor neo-vessels in specific tumors. Mobilization of endothelial progenitor cells (EPCs) from the bone marrow constitutes a crucial step in the formation of de novo blood vessels, and levels of peripheral blood EPCs have been shown to be increased in certain malignant states. However, the role of circulating EPCs in breast cancer is largely unknown. Methods: We recruited twenty-five patients with biopsy-proven invasive breast cancer (BC) at Weill Cornell Breast Center to participate in a pilot study investigating the correlation of circulating EPCs to extent of disease and initiation of chemotherapy. For each patient, a baseline sample was drawn before systemic treatment, and for seventeen of those patients, a second sample was taken after the first round of chemotherapy. Levels of peripheral blood EPCs, as defined by co-expression of CD133 and VEGFR2, were quantified by flow cytometry. Results: BC patients with stage III & IV disease had statistically higher levels of circulating EPCs than did patients with stage I & II disease (median=165,000 EPCs/5×106MNCs vs. median=6,920 EPCs/5x106MNCs, respectively, p < 0.0001 by Wilcoxon rank-sum test). In addition, in late-stage patients, levels of EPCs demonstrated a statistically significant drop after initiation of chemotherapy (median=162,500 EPCs/5x106MNCs [pre] vs. median=117,500 EPCs/5x106MNCs [post], p = 0.01 by Wilcoxon signed-rank test). Conclusion: These results suggest that circulating EPCs may serve as a potential tumor biomarker in breast cancer and that EPCs may represent a plausible target for future therapeutic intervention. Supported in part by the Mentored Medical Student in Clinical Research Program (General Clinical Research Center/National Institutes of Health Grant M01RR00047), Madeline & Stephen Anbinder Clinical Scholar Award, and Anne Moore Breast Cancer Research Fund No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Naik
- Weill Medical College of Cornell University, New York, NY
| | - D. Jin
- Weill Medical College of Cornell University, New York, NY
| | - E. Chuang
- Weill Medical College of Cornell University, New York, NY
| | - E. Gold
- Weill Medical College of Cornell University, New York, NY
| | - E. Tousimis
- Weill Medical College of Cornell University, New York, NY
| | - P. Christos
- Weill Medical College of Cornell University, New York, NY
| | - T. De Dalmas
- Weill Medical College of Cornell University, New York, NY
| | - D. Donovan
- Weill Medical College of Cornell University, New York, NY
| | - S. Rafii
- Weill Medical College of Cornell University, New York, NY
| | - L. Vahdat
- Weill Medical College of Cornell University, New York, NY
| |
Collapse
|
32
|
Hayes M, Katovic NM, Donovan D, Emmons S, Benavides M, Montalto M, Ryan CW, Liu G, Beer TM. Acupuncture for hot flashes in prostate cancer patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8160] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Hayes
- Oregon Health & Science Univ, Portland, OR
| | | | - D. Donovan
- Oregon Health & Science Univ, Portland, OR
| | - S. Emmons
- Oregon Health & Science Univ, Portland, OR
| | | | | | - C. W. Ryan
- Oregon Health & Science Univ, Portland, OR
| | - G. Liu
- Oregon Health & Science Univ, Portland, OR
| | - T. M. Beer
- Oregon Health & Science Univ, Portland, OR
| |
Collapse
|
33
|
Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant 2002; 30:149-55. [PMID: 12189532 DOI: 10.1038/sj.bmt.1703592] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2002] [Accepted: 03/25/2002] [Indexed: 11/09/2022]
Abstract
A single high-dose cycle of chemotherapy can produce response rates in excess of 50%. However, disease-free survival (DFS) is 15-20% at 5 years. The single most important predictor of prolonged DFS is achieving a complete response (CR). Increasing the proportion of patients who achieve a complete response may improve disease-free survival. Women with metastatic breast cancer and at least a partial response (PR) to induction chemotherapy received three separate high-dose cycles of chemotherapy with peripheral blood progenitor support and G-CSF. The first intensification was paclitaxel (825 mg/m(2)), the second melphalan (180 mg/m(2)) and the third consisted of cyclophosphamide 6000 mg/m(2) (1500 mg/m(2)/day x 4), thiotepa 500 mg/m(2) (125 mg/m(2)/day x 4) and carboplatin 800 mg/m(2) (200 mg/m(2)/day x 4) (CTCb). Sixty-one women were enrolled and 60 completed all three cycles. Following the paclitaxel infusion most patients developed a reversible, predominantly sensory polyneuropathy. Of the 30 patients with measurable disease, 12 converted to CR, nine converted to a PR*, and five had a further PR, giving an overall response rate of 87%. The toxic death rate was 5%. No patient progressed on study. Thirty percent are progression-free with a median follow-up of 31 months (range 1-43 months) and overall survival is 61%. Three sequential high-dose cycles of chemotherapy are feasible and resulted in a high response rate. The challenge continues to be maintenance of response and provides the opportunity to evaluate strategies for eliminating minimal residual disease.
Collapse
Affiliation(s)
- L T Vahdat
- Weill Cornell Medical College, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Angiogenesis assays are an important tool for studying both the mechanisms of angiogenesis and the potential development of therapeutic strategies to modulate neovascularisation. In vivo angiogenesis assays are considered to be the most informative of these but are often expensive, time-consuming and require specialist training to perform. In vitro assays tend to be more rapid, less expensive and easier to interpret. In vitro angiogenesis assays operate on the principle that endothelial cells form tubule-like structures when cultured on a supportive matrix. Assays involving a matrix derived from murine tumours, Matrigel (or a growth factor reduced form of this), are now the most common in vitro tubule formation assays. However, another tubule formation assay has recently been developed in which endothelial cells are co-cultured with fibroblasts. Here, we have used quantitative image analysis to compare the morphological features of tubules formed in the Matrigel assay and this new 'Co-culture' assay, with those of capillaries formed in a microvascular bed in vivo. Tubules formed in standard and growth factor reduced Matrigel assays were short and relatively homogeneous, whereas those formed in the Co-culture assay were significantly more heterogeneous, consisting of both short and long interconnecting tubules that more closely resembled capillaries than Matrigel tubules. Moreover, cells on Matrigel, and to a lesser extent growth factor reduced (GFR) Matrigel, often clumped into large cell aggregates, a feature rarely seen in the Co-culture assay. In addition, we demonstrate that Matrigel stimulates tubule formation by various non-endothelial cell types, suggesting that tubule formation by endothelial cells may not represent true differentiation of this cell type. In summary, the morphology of tubules in the Co-culture assay appears more representative of capillary formation in vivo, than the endothelial cell changes that occur in either form of Matrigel assay.
Collapse
Affiliation(s)
- D Donovan
- Tumour Targeting Group, Division of Genomic Medicine, University of Sheffield Medical School, Sheffield S10 2RX, UK
| | | | | | | |
Collapse
|
35
|
Mazzeo RS, Donovan D, Fleshner M, Butterfield GE, Zamudio S, Wolfel EE, Moore LG. Interleukin-6 response to exercise and high-altitude exposure: influence of alpha-adrenergic blockade. J Appl Physiol (1985) 2001; 91:2143-9. [PMID: 11641355 DOI: 10.1152/jappl.2001.91.5.2143] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Interleukin-6 (IL-6), an important cytokine involved in a number of biological processes, is consistently elevated during periods of stress. The mechanisms responsible for the induction of IL-6 under these conditions remain uncertain. This study examined the effect of alpha-adrenergic blockade on the IL-6 response to acute and chronic high-altitude exposure in women both at rest and during exercise. Sixteen healthy, eumenorrheic women (aged 23.2 +/- 1.4 yr) participated in the study. Subjects received either alpha-adrenergic blockade (prazosin, 3 mg/day) or a placebo in a double-blinded, randomized fashion. Subjects participated in submaximal exercise tests at sea level and on days 1 and 12 at altitude (4,300 m). Resting plasma and 24-h urine samples were collected throughout the duration of the study. At sea level, no differences were found at rest for plasma IL-6 between groups (1.5 +/- 0.2 and 1.2 +/- 0.3 pg/ml for placebo and blocked groups, respectively). On acute ascent to altitude, IL-6 levels increased significantly in both groups compared with sea-level values (57 and 84% for placebo and blocked groups, respectively). After 12 days of acclimatization, IL-6 levels remained elevated for placebo subjects; however, they returned to sea-level values in the blocked group. alpha-Adrenergic blockade significantly lowered the IL-6 response to exercise both at sea level (46%) and at altitude (42%) compared with placebo. A significant correlation (P = 0.004) between resting IL-6 and urinary norepinephrine excretion rates was found over the course of time while at altitude. In conclusion, the results indicate a role for alpha-adrenergic regulation of the IL-6 response to the stress of both short-term moderate-intensity exercise and hypoxia.
Collapse
Affiliation(s)
- R S Mazzeo
- Department of Kinesiology and Applied Physiology, University of Colorado, Boulder, Colorado 80309, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res 2001; 7:1192-7. [PMID: 11350883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
PURPOSE Dose-limiting toxicity of many newer chemotherapeutic agents is peripheral neuropathy. Prior attempts to reduce this side effect have been unsuccessful. We report on the possible successful reduction of peripheral neuropathy with glutamine administration after high-dose paclitaxel. EXPERIMENTAL DESIGN Patients entered a high-dose chemotherapy protocol in which the first high-dose cycle was paclitaxel at 825 mg/m(2) given over 24 h. The first cohort of patients did not receive glutamine, and the second cohort of patients received glutamine at 10 g orally three times a day for 4 days starting 24 h after completion of paclitaxel. Neurological assessment was performed at baseline, and at least 2 weeks after paclitaxel, and consisted of a complete neurological exam and nerve conduction studies. RESULTS There were paired pre- and post-paclitaxel evaluations on 33 patients who did not receive glutamine and 12 patients who did. The median interval between pre- and post-exams was 32 days. For patients who received glutamine, there was a statistically significant reduction in the severity of peripheral neuropathy as measured by development of moderate to severe dysesthesias and numbness in the fingers and toes (P < 0.05). The degree and incidence of motor weakness was reduced (56 versus 25%; P = 0.04) as well as deterioration in gait (85 versus 45%; P = 0.016) and interference with activities of daily living (85 versus 27%; P = 0.001). Moderate to severe paresthesias in the fingers and toes were also reduced (55 versus 42% and 64 versus 50%, respectively), although this value was not statistically significant. All of these toxicities were reversible over time. CONCLUSIONS Glutamine may reduce the severity of peripheral neuropathy associated with high-dose paclitaxel; however, results from randomized, placebo-controlled clinical trials will be needed to fully assess its impact, if any. Trials are currently ongoing to assess its efficacy for standard-dose paclitaxel in breast cancer and other tumors for which peripheral neuropathy is the dose-limiting toxicity.
Collapse
Affiliation(s)
- L Vahdat
- Division of Medical Oncology and Hematology, Department of Medicine, The Herbert Irving Comprehensive Cancer Center of Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Rosatte R, Donovan D, Allan M, Howes LA, Silver A, Bennett K, MacInnes C, Davies C, Wandeler A, Radford B. Emergency response to raccoon rabies introduction into Ontario. J Wildl Dis 2001; 37:265-79. [PMID: 11310877 DOI: 10.7589/0090-3558-37.2.265] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
During 15 July to 4 October, 1999, rabies control programs were implemented with the objective being to contain the first three confirmed cases of raccoon rabies in Canada. The strategy, called point infection control (PIC) involved the use of three tactics: population reduction (PR), trap-vaccinate-release (TVR) and oral rabies vaccination with baits (ORV), to control the spread of raccoon rabies. A total of 1,202 raccoons (Procyon lotor) and 337 skunks (Mephitis mephitis) were captured and euthanized using 24,719 trap-nights in the three PR zones around the location of the three rabies cases, near Brockville, Ontario. That represented an 83% to 91% reduction in the raccoon populations in an approximate 225 km2 area around the three rabies cases. Raccoon density in the PR zones declined from 5.1-7.1/km2 to 0.6-1.1/km2 following control. All tested specimens were negative for rabies by the fluorescent antibody test (FAT). In addition, 1,759 raccoons and 377 skunks were intramuscularly vaccinated against rabies and released using 27,956 trap-nights in an approximate 485 km2 TVR zone implemented outside of the PR zones. A total of 856 cats from both PR and TVR areas were also captured, vaccinated and released. Cost for the three PIC operations was $363,000.00 Cdn or about $500.00 Cdn/km2. To further contain the outbreak, about 81,300 baits containing Raboral V-RG oral rabies vaccine were aerially distributed on 8 and 27 September 1999, to create an 8 to 15 km wide buffer zone (1,200 km2 area) of vaccinated raccoons immediately beyond the PR and TVR zones. This was the first time that V-RG was used in Canada to orally vaccinate free ranging raccoons against rabies. Baiting costs were $241,000.00 Cdn or about $200.00 Cdn/km2 including post baiting assessment costs. As of 31 August, 2000, thirty-five additional cases (38 in total) of raccoon rabies have occurred in the control and vaccination zones. This number is far below the level of rabies prevalence in USA jurisdictions where raccoon rabies was epizootic. In the future, PIC methodologies will continue to be used in Ontario to contain isolated cases of raccoon rabies.
Collapse
Affiliation(s)
- R Rosatte
- Ontario Ministry of Natural Resources, Rabies Research Unit, Trent University, Peterborough, Canada.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
BACKGROUND Addressing non-alcoholic, at-risk patterns of alcohol consumption that are associated with increased morbidity and mortality is an important health care priority. OBJECTIVE The objective was to describe the prevalence and characteristics of at-risk drinkers in a population-based sample of adults with routine primary care visits. METHODS Three thousand four hundred thirty-nine patients with advance appointments in 23 primary care practices completed a health survey prior to their visit. At-risk drinking was defined as consuming an average of two or more drinks per day (chronic drinking), or two or more occasions of consuming five or more drinks in the past month (binge drinking), or, in the past month, one or more occasion of driving after consuming three or more drinks (drinking and driving). RESULTS Prevalence was: 11% at-risk drinking; 63% light to moderate drinking; 26% abstinence. Abstainers differed from alcohol users on demographics (older, fewer Caucasian, lower income, more unemployed), other health behaviors (less exercise, lower rates of smoking, and marijuana and cocaine use), and family history of alcohol problems (lower). Abstainers also reported poorer physical and psychological health. Compared to light to moderate drinkers, at-risk drinkers were more likely to be male, unmarried, and to use other substances (tobacco, marijuana, and cocaine). Among at-risk drinkers, those with two or more risk factors were more likely male, consumed more alcohol per week, had higher AUDIT scores and were more motivated to change their drinking. Among those with only one risk factor, binge drinkers reported high rates of tobacco and marijuana use, relatively poor perceived health, and the highest proportion of negative consequences from drinking. CONCLUSIONS At least 1 in 10 patients making routine primary care visits have drinking practices that place them at risk for negative consequences from drinking. Three drinking patterns that can be used to define at-risk drinking are relatively distinct.
Collapse
Affiliation(s)
- S J Curry
- Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA.
| | | | | | | | | | | |
Collapse
|
39
|
Douketis JD, Crowther MA, Julian JA, Stewart K, Donovan D, Kaminska EA, Laskin CA, Ginsberg JS. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost 1999; 82:1028-32. [PMID: 10494759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The optimal intensity of oral anticoagulant therapy for the prevention of thromboembolism in patients with antiphospholipid antibodies (APLA) and systemic lupus erythematosus is controversial. Retrospective studies have suggested that patients with APLA are resistant to oral anticoagulant therapy, with a targeted International Normalization Ratio (INR) of 2.0 to 3.0, and that a higher intensity of anticoagulation (INR: 2.6 to 4.5) is required to prevent recurrent thromboembolism. To investigate if patients with APLA are resistant to the anticoagulant effect of low intensities of warfarin therapy, we performed a randomized trial in which 21 patients with APLA and systemic lupus erythematosus were allocated to receive one of three intensities of warfarin (INR: 1.1 to 1.4, 1.5 to 1.9 or 2.0 to 2.5) or placebo for four months. The main outcome was the effect of each intensity of warfarin therapy on prothrombin fragment 1+2 level (F1+2), that was used as a marker of coagulation activation. When F1+2 levels in patients allocated to the three warfarin intensities were compared to F1+2 levels in the placebo group, there was a statistically significant decrease (p<0.05) in the patient group receiving warfarin with a targeted INR of 2.0 to 2.5 at two, three and four months, and in the patient group with a targeted of INR 1.5 to 1.9 at three months. We conclude that in patients with APLA and systemic lupus erythematosus, warfarin therapy, with a targeted INR of 2.0 to 2.5, is effective in suppressing coagulation activation, and therefore, might be effective in preventing thromboembolism.
Collapse
Affiliation(s)
- J D Douketis
- Department of Medicine, McMaster University, Hamilton, Canada.
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
BACKGROUND Osteoporosis is very common in patients with end-stage pulmonary disease. However, there are few prospective data on fracture incidence after lung transplantation. METHODS We prospectively evaluated changes in bone mass, fracture incidence, and biochemical indices of bone and mineral metabolism in 30 patients who completed 1 year of observation after lung transplantation. All received calcium, vitamin D, and therapy with one or more agents that inhibit bone resorption, initiated shortly after transplantation. RESULTS Before transplantation, only 20% of the patients had normal lumbar spine (LS) and femoral neck bone mineral density (BMD). After transplantation, 15 patients (50%) sustained significant bone loss at either the LS (-8.6+/-1.0%) or the femoral neck (-11.3+/-2.2%). Eleven (37%) patients (10 women) sustained a total of 54 atraumatic fractures. Pretransplantation LS BMD and T scores were significantly lower in those who sustained fractures (-2.809+/-0.32 versus -1.569+/-0.29; P<0.01). Fracture patients were more likely to have had pretransplantation glucocorticoid therapy (chi-square 5.687; P<0.02). The duration of pretransplantation glucocorticoid therapy was also longer in fracture patients (4.9+/-0.8 versus 1.3+/-0.4 years; P<0.001). Biochemical markers of bone resorption were significantly higher in patients who sustained bone loss and/or fractures. CONCLUSIONS We conclude that fractures are a significant problem in the first year after lung transplantation, even in patients who receive therapy to prevent bone loss. Women with low pretransplantation BMD and a history of pretransplantation glucocorticoid therapy are at greatest risk.
Collapse
Affiliation(s)
- E Shane
- Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Over the past 30 years, numerous studies in invertebrates and vertebrates have established a role of calcium in oocyte maturation as well as in the resumption and progression of follicular development. Polycystic ovarian syndrome (PCO) is characterized by hyperandrogenic chronic anovulation, theca cell hyperplasia, and arrested follicular development. The aim of this observational study was to determine whether vitamin D and calcium dysregulation contribute to the development of follicular arrest in women with PCO, resulting in reproductive and menstrual dysfunction. Thirteen premenopausal women (mean age 31 +/- 7.9 years) with documented chronic anovulation and hyperandrogenism were evaluated. Four women were amenorrheic and nine had a history oligomenorrhea, two of whom had dysfunctional bleeding. Nine had abnormal pelvic sonograms with multiple ovarian follicular cysts. All were hirsute, two had alopecia, and five had acanthosis nigricans. The mean 25 hydrovitamin D was 11.2 +/- 6.9 ng/ml [normal (nl): 9-52], and the mean 1,25 dihydroxyvitamin D was 45.8 +/- 18 pg/ml. with one woman with a 1,25 dihydroxyvitamin D <5 pg/ml (nl: 15-60). The mean intact parathyroid hormone level was 47 +/- 19 pg/ml (nl: 10-65), with five women with abnormally elevated parathyroid hormone levels. All were normocalcemic (9.3 +/- 0.4 mg/dl). Vitamin D repletion with calcium therapy resulted in normalized menstrual cycles within 2 months for seven women, with two experiencing resolution of their dysfunctional bleeding. Two became pregnant, and the other four patients maintained normal menstrual cycles. These data suggest that abnormalities in calcium homeostasis may be responsible, in part, for the arrested follicular development in women with PCO and may contribute to the pathogenesis of PCO.
Collapse
Affiliation(s)
- S Thys-Jacobs
- Department of Medicine, St. Lukes-Roosevelt Hospital Center, Columbia University, College of Physicians & Surgeons, New York, NY 10019, USA
| | | | | | | | | |
Collapse
|
42
|
Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, Working P. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999; 80:134-7. [PMID: 9935243 DOI: 10.1002/(sici)1097-0215(19990105)80:1<134::aid-ijc24>3.0.co;2-q] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We compared the therapeutic effects of low doses of cisplatin and doxorubicin hydrochloride encapsulated in long-circulating liposomes composed of cholesterol/hydrogenated soy phosphatidylcholine-polyethylene glycol-distearoyl-phosphatidyl-ethanolamine. The encapsulation of cisplatin and doxorubicin in these liposomes made ineffectively low doses of the free drugs able to inhibit the growth of and affect cures of a human colonic carcinoma growing in nude mice. Liposome-encapsulated cisplatin had minor systemic toxic side effects indicated by an average 9% weight loss which was recovered 3-4 weeks after the last treatment. Toxicity was not observed in mice treated with liposome-encapsulated doxorubicin.
Collapse
Affiliation(s)
- J Vaage
- Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Mattson ME, Del Boca FK, Carroll KM, Cooney NL, DiClemente CC, Donovan D, Kadden RM, McRee B, Rice C, Rycharik RG, Zweben A. Compliance with treatment and follow-up protocols in project MATCH: predictors and relationship to outcome. Alcohol Clin Exp Res 1998; 22:1328-39. [PMID: 9756050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Treatment and follow-up session attendance data from Project MATCH, a multisite clinical trial investigating patient-treatment matching, were analyzed to study compliance. High rates of compliance to both therapy and research protocols were achieved, enhancing treatment integrity and data quality. Strong baseline predictors of compliance did not emerge, and the small relationships found were consistent with reports from previous studies. Attendance at therapy sessions was moderately correlated with research follow-up participation. Treatment compliance predicted drinking outcome, underscoring the importance of retaining patients in treatment. Future studies should examine the associations between compliance and structural features of the treatment environment, treatment delivery, and context-features that are often under the control of the clinician/investigator.
Collapse
Affiliation(s)
- M E Mattson
- National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland 20892-7003, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Goldberger JJ, Horvath G, Donovan D, Johnson D, Challapalli R, Kadish AH. Detection of ventricular fibrillation by transvenous defibrillating leads: integrated versus dedicated bipolar sensing. J Cardiovasc Electrophysiol 1998; 9:677-88. [PMID: 9684715 DOI: 10.1111/j.1540-8167.1998.tb00954.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Dedicated bipolar sensing has been suggested to be safer than integrated bipolar sensing due to an increased incidence of failure to redetect ventricular fibrillation after an unsuccessful shock with leads that use integrated bipolar sensing. We compared sensing characteristics during ventricular fibrillation of simultaneously recorded dedicated and integrated bipolar electrograms. METHODS AND RESULTS Thirty patients undergoing transvenous defibrillator implantation with a Transvene lead were studied. Simultaneous recordings were made from the dedicated bipole and the integrated bipole from the distal tip to the coil (interelectrode distance 18.3 mm). The mean detection time and number of undetected beats for the initial episode of ventricular fibrillation were 2804 +/- 569 msec and 0.9 +/- 0.8 using the dedicated recordings and 2938 +/- 546 msec and 1.4 +/- 1.1 (P = 0.026) using the integrated recordings. The mean redetection times and number of undetected beats following a failed first shock (n = 13) were 2468 +/- 225 msec and 0.8 +/- 1.1 for the dedicated recordings and 3042 +/- 498 msec (P < 0.0003) and 4.2 +/- 4.2 (P < 0.005) for the integrated recordings. Frequency analysis of the ventricular fibrillation electrograms demonstrated that the signal energy in the dedicated electrograms was significantly greater than the energy in the integrated electrograms (P < 0.0001). There was a significant negative relationship between detection times and the ventricular fibrillation signal energy. There was no independent effect of recording type (dedicated versus integrated). CONCLUSION There are only minor differences in detection/redetection of ventricular fibrillation between dedicated and integrated (with tip to coil spacing of 18.3 mm) recording configurations. Detection times during ventricular fibrillation are related to the signal variance or energy recorded. Differences in the sensing performance of the two recording configurations can be explained by the differences in signal energy between the dedicated and integrated recordings that occur during ventricular fibrillation.
Collapse
Affiliation(s)
- J J Goldberger
- Department of Medicine, and Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, Illinois, USA.
| | | | | | | | | | | |
Collapse
|
45
|
Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 1998; 79:1116-8. [PMID: 9657434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Patients receiving long-term warfarin frequently develop asymptomatic excessive prolongation of their international normalized ratio (INR) results. The most appropriate management strategy in these patients is unknown. This prospective cohort study was designed to address whether 1 mg of oral vitamin K effectively reduces the INR value of such patients. METHODS A prospective cohort study was performed in two tertiary care teaching hospitals, in which 62 patients receiving warfarin who had INR values between 4.5 and 10.0 received 1 mg of oral vitamin K. All patients had daily INR values and clinical assessments performed. RESULTS The mean INR value at presentation was 5.79 (95% confidence interval (CI) 5.48 to 6.09, range 4.5 to 9.5). Sixteen hours after receiving the 1 mg of oral vitamin K, the mean INR was 2.86 (95% CI 2.50 to 3.23). On the second and third days after vitamin K, the mean INR values were 2.20 (1.93 to 2.47) and 2.14 (1.85 to 2.44), respectively. No adverse events or bleeding complications were observed. In three patients (6%) the INR value rose between the time of vitamin K administration and the next INR determination; two patients received a further 2 mg dose of subcutaneous vitamin K. CONCLUSIONS In patients receiving warfarin who have asymptomatic excessive prolongations in their INR results, 1 mg of oral vitamin K reliably reduces the INR to the therapeutic range within 24 h. This therapy is more convenient, less expensive, and might be safer than parenteral vitamin K. Thus, it should be considered in all non-bleeding patients receiving warfarin, who present with INR results of 4.5 to 9.5.
Collapse
Affiliation(s)
- M A Crowther
- Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada.
| | | | | | | | | |
Collapse
|
46
|
Willison HJ, Lastovica AJ, Prendergast MM, Moran AP, Walsh C, Flitcroft I, Eustace P, McMahon C, Smith J, Smith OP, Lakshmandass G, Taylor MRH, Holland CV, Cox D, Good B, Kearns GM, Gaffney P, Shark K, Frauenshuh M, Ortmann W, Messner R, King R, Rich S, Behrens T, Mahmud N, Molloy A, McPartlin J, Scott JM, Weir DG, Walsh KM, Thorburn D, Mills P, Morris AJ, Good T, Cameron S, McCruden EAB, Bennett MW, O’Connell J, Brady C, Roche D, Collins JK, Shanahan F, O’Sullivant GC, Henry M, Koston S, McMahon K, MacNee W, FitzGerald MX, O’Connor CM, McGonagle D, Gibbon W, O’Connor P, Emery P, Murphy M, Watson R, Casey E, Naidu E, Murphy M, Watson R, Barnes L, McCann S, Murphy M, Watson R, Barnes L, Sweeney E, Barrett EJ, Graham H, Cunningham RT, Johnston CF, Curry WJ, Buchanan KD, Courtney CH, McAllister AS, McCance DR, Hadden DR, Bell PM, Leslie H, Sheridan B, Atkinson AB, Kilbane MT, Smith DF, Murray MJ, Shering SG, McDermott EWM, O’Higgins NJ, Smyth PPA, McEneny J, Trimble ER, Young IS, Sharpe P, Mercer C, McMaster D, Young IS, Evans AE, Young IS, Cundick J, Hasselwander O, McMaster D, McGeough J, Savage D, Maxwell AP, Evans AE, Kee F, Larkin CJ, Watson RGP, Johnston C, Ardill JES, Buchanan KD, McNamara DA, Walsh TN, Bouchier-Hayes DJ, Madden C, Timon C, Gardiner N, Lawler M, O’Riordan J, Duggan C, McCann SR, Gowing H, Braakman E, Lawler M, Byrne C, Martens ACM, Hagenbeek A, McCann SR, Kinsella N, Cusack S, Lawler M, Baker H, White B, Smith OP, Lawler M, Gardiner N, Molloy K, Gowing H, Wogan A, McCann SR, McElwaine S, Lawler M, Hollywood D, McCann SR, Mcmahon C, Merry C, Ryan M, Smith O, Mulcahy FM, Murphy C, Briones J, Gardiner N, McCann SR, Lawler M, White B, Lawler M, Cusack S, Kinsella N, Smith OP, Lavin P, McCaffrey M, Gillen P, White B, Smith OP, Thompson L, Lalloz M, Layton M, Barnes L, Corish C, Kennedy NP, Flood P, Mulligan S, McNamara E, Kennedy NP, Flood P, Mathias PM, Ball E, Duiculescu D, Calistru P, O’Gorman N, Kennedy NP, Abuzakouk M, Feighery C, Brannigan M, Pender S, Keeling F, Varghese J, Lee M, Colreavy M, Gaffney R, Hone S, Herzig M, Walsh M, Dolan C, Wogan A, Lawler M, McCann SR, Hollywood D, Donovan D, Harmey J, Bouchier-Hayes DJ, Haverty A, Wang JH, Harmey JH, Redmond HP, Bouchier-Hayes DJ, McGreal G, Shering SG, Moriarty MJ, Shortt A, Kilbane MT, Smith DF, McDermott EWM, O’Higgins NJ, Smyth PPA, McNamara DA, Harmey J, Wang JH, Donovan D, Walsh TN, Bouchier-Hayes DJ, Kay E, Pidgeon G, Harmey J, McNamara DA, Bouchier-Hayes DJ, Dunne P, Lambkin H, Russell JM, O’Neill AJ, Dunne BM, O’Donovan M, Lawler M, Gaffney EF, Gillan JE, Cotter TG, Horan J, Jones D, Biswas SK, Mulkerrin EC, Brady H, O’Donnell J, Neary J, Healy E, Watson A, Keogh B, Ryan M, Cassidy C, Ward S, Stokes E, Keoghan F, Barrett A, O’Connell P, Ryall N, O’Connell PA, Jenkinson A, O’Brien T, O’Connell PG, Harrison R, Barrett T, Bailey DMD, Butler A, Barton DE, Byrne C, McElwaine S, McCann SR, Lawler M, Cusack S, Lawler M, White B, Smith OP, Daly G, Gill M, Heron S, Hawi Z, Fitzgerald M, Hawi Z, Mynett-Johnson L, Shiels D, Kendler K, McKeon P, Gill M, Straub R, Walsh D, Ryan F, Barton DE, McCabe D, Murphy R, Segurado R, Mulcahy T, Larson B, Comerford C, O’Connell R, O’Mahony E, Gill M, Donnelly J, Minahan F, O’Neill D, Farrell Z, O’Neill D, Jones D, Horan J, Glynn C, Biswas SK, Mulkerrin E, Brady H, Lennox SE, Murphy A, Rea IM, McNulty H, McMeel C, O’Neill D, McEvoy H, Freaney R, McKenna MJ, Crowe M, Keating D, Colreavy M, Hone S, Norman G, Widda S, Viani L, Galvin, Nolan CM, Hardiman O, Hardiman O, Brett F, Droogan O, Gallagher P, Harmey M, King M, Murphy J, Perryrnan R, Sukumaran S, Walsh J, Farrell MA, Hughes G, Cunningham C, Walsh JB, Coakley D, O’Neill D, Hurson M, Flood P, McMonagle P, Hardiman O, Ryan F, O’Sullivan S, Merry C, Dodd P, Redmond J, Mulcahy FM, Browne R, Keating S, O’Connor J, Cassidy BP, Smyth R, Sheppard NP, Cullivan R, Crown J, Walsh N, Denihan A, Bruce I, Radic A, Coakley D, Lawlor BA, Bridges PK, O’Doherty M, Farrington A, O’Doherty M, Farragher B, Fahy S, Kelly R, Carey T, Owens J, Gallagher O, Sloan D, McDonough C, Casey P, Horgan A, Elneihum A, O’Neill C, McMonagle T, Quinn J, Meagher D, Murphy P, Kinsella A, Mullaney J, Waddington JL, Rooney S, Rooney S, Bamford L, Sloan D, O’Connor JJ, Franklin R, O’Brien K, Fitzpatrick G, Laffey JG, Boylan JF, Laffey J, Coleman M, Boylan J, Laffey JG, McShane AJ, Boylan JF, Loughrey JPR, Gardiner J, McGinley J, Leonard I, Carey M, Neligan P, O’Rourke J, Cunningham A, Fennessy F, Kelly C, Bouchier-Hayes D, Fennessy F, Wang JH, Kelly C, Bouchier-Hayes D, Fennessy F, Wang JH, Kelly C, Bouchier-Hayes DJ, Kellett J, Laffey J, Murphy D, Regan J, O’Keeffe D, Mahmud A, Hemeryck L, Feely J, Mahmud A, Hemeryck L, Hall M, Feely J, Menown IBA, Mathew TP, Nesbitt GS, Syme M, Young IS, Adgey AAJ, Menown IBA, Turtle F, Allen J, Anderson J, Adgey AAJ, O’Hanlon R, Codd MB, Walkin S, McCann HA, Sugrue DD, Rasheed AM, Chen G, Kelly C, Bouchier-Hayes DJ, Leahy A, Rasheed AM, Kay E, Jina S, Bouchier-Hayes DJ, Leahy A, McDowell I, Rasheed AM, Wang JH, Wo Q, Kelly C, Bouchier-Hayes DJ, Leahy A, Shuhaibar MN, McGovern E, Turtle F, Menown IBA, Manoharan G, Kirkpatrick R, Campbell NPS, Walkin S, Codd MB, O’Hanlon R, McCarthy C, McCann HA, Sugrue DD, Wen Y, Killalea S, Hall M, Hemeryck L, Feely J, Fahy CJ, Griffith A, McGinley J, McCabe D, Fraser A, Casey E, Ryan T, Murphy R, Browne M, Fenton J, Hughes J, Timon CI, Fenton J, Curran A, Smyth D, Viani L, Walsh M, Hughes JP, Fenton J, Lee P, Kelly A, Timon CI, Hughes JP, Fenton J, Shine N, Blayney A, McShane DP, Timon CI, Hussey J, Howlett M, Langton A, McEvoy A, Slevin J, Fitzpatrick C, Turner MJ, Enright F, Goggin N, Costigan C, Duff D, Osizlok P, Wood F, Watson R, Fitzsimons RB, Flanagan N, Enright F, Barnes L, Watson R, Molloy E, Griffin E, Deasy PF, Sheridan M, White MJ, Moore R, Gray A, Hill J, Glasgow JFT, Middleton B, Slattery D, Donoghue V, McMahon A, Murphy J, Slattery D, McCarthy A, Oslislok P, Duff D, Colreavy M, Keogh I, Hone S, Walsh M, Henry M, Koston S, McMahon K, MacNee W, FitzGerald MX, O’Connor CM, Russell KJ, Henry M, Fitzgerald MX, O’Connor CM, Kavanagh PV, McNamara SM, Feely J, Barry M, O’Brien JE, McCormick P, Molony C, Doyle RM, Walsh JB, Coakley D, Codd MB, O’Connell PR, Dowey LC, McGlynn H, Thurnham DI, Elborn SJ, Flynn L, Carton J, Byrne B, O’Farrelly C, Kelehan P, O’Herlihy C, O’Hara AM, Moran AP, Orren A, Fernie BA, Merry C, Clarke S, Courtney G, de Gascun C, Mulcahy FM, Merry C, Ryan M, Barry M, Mulcahy FM, Merry C, Ryan M, Barry M, Mulcahy FM, Byrne M, Moylett E, Murphy H, Butler K, Nourse C, Thaker H, Barry C, Russell J, Sheehan G, Boyle B, Hone R, Conboy B, Butler C, Moris D, Cormican M, Flynn J, McCormack O, Corbally N, Murray A, Kirrane S, O’Keane C, Hone R, Lynch SM, Cryan B, Whyte D, Morris D, Butler C, Cormican M, Flynn J, Corbett-Feeney G, Murray A, Corbally N, Hone R, Mackle T, Colreavy M, Perkins J, Saidlear C, Young A, Eustace P, Wrigley M, Clifford J, Waddington JL, Tighe O, Croke DT, Drago J, Sibley DR, Feely J, Kelly A, Carvalho M, Hennessy M, Kelly M, Feely J, Hughes C, Hanlon M, Feely J, Sabra K, Keane T, Egan D, Ryan M, Maerry C, Ryan M, Barry M, Mulcahy FM, Maerry C, Ryan M, Barry M, Mulcahy FM, Sharma SC, Williams D, Kelly A, Carvalho M, Feely J, Williams D, Kelly A, Carvalho M, Feely J, Codd MB, Mahon NG, McCann HA, Sugrue DD, Sayers GM, Johnson Z, McNamara SM, Kavanagh PV, Feely J. National scientific medical meeting 1997 abstracts. Ir J Med Sci 1998. [DOI: 10.1007/bf02937234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Relihan N, McGreal G, Murray M, McDermott EW, O’Higgins NJ, Duffy MJ, McNamara DA, Harmey J, Wang JH, Donovan D, Walsh TN, Bouchier-Hayes DJ, Kay E, Kelly JD, Weir HP, Keane PF, Johnston SR, Williamson KE, Hamilton PW, McManus D, Morrin M, Delaney PV, Winter DC, Harvey BJ, Geibel JP, O’Sullivan GC, Delaney CP, Coffey R, Gorey TF, Fitzpatrick JM, Fanning NF, Kirwan W, Cotter T, Bouchier-Hayes D, Redmond HP, McNamara DA, Pidgeon G, Harmey J, Walsh TN, Bouchier-Hayes DJ, Redmond HP, Fennessy F, Wang JH, Kelly C, Bouchier-Hayes D, Delaney CP, Flavin R, Coffey R, Gorey TF, Fitzpatrick JM, Rasheed AM, Wang JH, Kelly C, Bouchier-Hayes DJ, Leahy A, Lang EE, Caldwell MTP, Tanner WA, Kiely PD, O’Reilly M, Tierney S, Barry M, Delaney PV, Drumm J, Grace PA, Gallagher CM, Grant DC, Connell P, Barry MK, Traynor O, Hyland JMP, O’Sullivan MJ, Evoy D, Redmond HP, Kirwan WO, Cannon B, Kenny-Walshe L, Whelton MJ, O’Grady H, O’Neill S, Grant DC, Barry MK, Traynor O, Hyland JM, Teh SH, O’Ceallaigh S, O’Donohoe MK, Tanner WA, Keane FB, O’Toole GC, Grant DC, Barry MK, Hyland JMP, Calleary J, Basso L, Amjad SB, Khan Z, McMullin L, Joyce WP, Balfe PJ, Caldwell MT, Keane FB, Tanner WA, Teahan S, Al-Brekeit K, Tierney S, Rasheed A, Bouchier-Hayes D, Leahy A, O’Neill S, Delaney CP, Gorey TF, Fitzpatrick JM, Cullen A, O’Keane C, Fennessy F, Kelly C, Bouchier-Hayes D, Fennessy F, Wang JH, Kelly C, Bouchier-Hayes DJ, Winter DC, MacFarlane J, Harvey BJ, O’Sullivan GC, Walsh M, McGloughlin T, Grace P, Colgan D, Madhavan P, Sultan S, Colgan MP, Moore D, Shanik G, McEniff N, Molloy M, Eguare E, Fiuza C, Grace P, Burke P, Maher R, Creamer M, Cronin CJ, Sigurdsso HH, Kim W, Linklater G, Cross KS, Simpson WG, Shaw JAM, Pearson DWM, Fitzgerald P, Quinn P, Tierney S, Bouchier-Hayes D, Brady CM, Shah SMA, Ehtisham M, Khan MS, Flood HD, Loubani M, Sweeney K, Lenehan B, Lynch V, Joy A, McGreal G, Reidy D, Mahalingam K, Cashman W, Mulligan ED, Purcell T, Dunne B, Griffin M, Noonan N, Hollywood D, Keeling N, Reynolds JV, Hennessy TPJ, O’Halloran D, McGreal G, McDermott EW, O’Higgins NJ, Neary P, Hamilton D, Haider N, Aherne N, Watson RGK, Walsh D, Murphy M, Joyce M, Johnston S, Clinton O, Given HF, Brannigan A, O’Donohoe M, Donohoe J, Corrigan T, Bresnihan M, O’Donohoe MK, Feeley TM, Sultan S, Madhavan P, Colgan MP, Moore D, Shanik G, McMonagle MP, Quinlan D, Kelly D, Hegarty PK, Tan B, Cronin C, Brady MP, Zeeshan M, McAvinchey DJ, Aherne N, Mooney C, Coyle D, Haider N, Hamilton D, Neary P, Watson RGK, Khayyat G, Masterson E, Thambi-Pillai T, Farah K, Delaney CP, Codd MB, Fitzpatrick JM, Gorey TF, Barry MK, Tsiotos GG, Johnson CD, Sarr MG, Kell MR, Lynch M, Ryan D, O’Donovan A, Winter DC, Redmond HP, Delaney CP, Cassidy M, Doyle M, Fulton G, O’Connell PR, Kingston R, Dillon M, Barry M, Tierney S, Grace PA, McGreal G, Lenehan B, Murray M, McDermott E, O’Higgins N, Kell MR, O’Sullivan RG, Tan B, O’Donnell JA. Sylvester o’halloran surgical scientific meeting. Ir J Med Sci 1998. [DOI: 10.1007/bf02937403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Affiliation(s)
- D Donovan
- Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin
| | | | | | | |
Collapse
|
49
|
Abstract
BACKGROUND Angiogenesis is essential for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor identified to date. TGF beta-1 acts as an indirect angiogenic agent. METHODS VEGF and TGF beta-1 were measured in the serum of breast cancer patients and age-matched controls and in tumor tissue of cancer patients by ELISA. VEGF protein and mRNA expression by breast tumor cell lines were examined, and the effect of TGF beta-1 on VEGF production in these cells was assessed. RESULTS VEGF levels were significantly higher (P = .03) in the serum of patients with breast cancer compared to age-matched controls. A positive correlation was found between serum (r = 0.539) and tumor tissue (r = 0.688) levels of VEGF and TGF beta-1. Metastatic MDA-MB-231 breast cancer cells produce more VEGF than do the primary BT474 cells. TGF beta-1 significantly (P < .05) increased production of VEGF. CONCLUSIONS Breast cancer cells constitutively produce VEGF protein and mRNA. There is a relationship between VEGF and TGF beta-1 levels in breast cancer patients, and TGF beta-1 regulates VEGF expression by breast cancer cells.
Collapse
|
50
|
Abstract
Morphological analyses of pedal sole area and pedal waves were conducted for a range of speeds and body sizes in the abalone Haliotis kamtschatkana. The pedal sole of resting abalone increased in size disproportionately with animal volume (slope of log10-transformed data, b=0.83; expected slope for isometry, b0=0.67) and length (b=2.51; b0=2.0). Pedal wave frequency increased linearly with speed, confirming that abalone increase speed by increasing the velocity of pedal waves. Total area of the pedal sole decreased by 2.1 % for each shell length per minute increase in speed. Likewise, the area of the foot incorporated into pedal waves increased by 1.8 % for each shell length per minute increase in speed. Together, these changes translated into a 50 % decrease in the pedal sole area in contact with the substratum at a maximum escape speed of 15 shell lengths min-1, relative to the pedal sole at rest. The amount of mucus secreted by resting animals during adhesion to the substratum increased isometrically with foot area (slope of log10-transformed data, b=1.08). The amount of mucus secreted during locomotion did not vary with speed, but was less than the amount needed for adhesion. We suggest that these morphological and physiological changes reduce the energy expenditure during locomotion. Cost of transport was investigated for a range of speeds and abalone sizes. The rate of oxygen consumption O2 (in µl O2 g-1 h-1) increased linearly with increasing absolute speed v (in cm min-1): O2=40.1+0.58v-0.15m (r2=0.35, P=0.04), where m is body mass (in g). Minimum cost of transport, calculated from the slope of absolute speed on O2, was 20.3 J kg-1 m-1. Total cost of transport (COTT) and net cost of transport (COTN) were high at low speeds and decreased as speed increased, to minima of 86.0 J kg-1 m-1 and 29.7 J kg-1 m-1, respectively, at speeds measured in the respirometer. Log10-transformation of both cost of transport and speed data yielded linear relationships with the following regression equations: log10COTT=3.35-0.90log10v-0.21log10m (r2=0.89; P<0.006) and log10COTN=2.29-0.69log10v-0.09log10m (r2=0.48; P<0.006), respectively.
Collapse
|